Verrica Pharmaceuticals (VRCA)
(Delayed Data from NSDQ)
$4.39 USD
+0.35 (8.66%)
Updated Sep 19, 2025 04:00 PM ET
After-Market: $4.32 -0.07 (-1.59%) 4:32 PM ET
3-Hold of 5 3
F Value D Growth A Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
VRCA 4.39 +0.35(8.66%)
Will VRCA be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for VRCA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for VRCA
Verrica Pharmaceuticals Inc. (VRCA) Q2 Earnings and Revenues Beat Estimates
Soleno Therapeutics, Inc. (SLNO) Reports Q2 Loss, Tops Revenue Estimates
VRCA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Verrica Pharmaceuticals Inc. (VRCA) Reports Q1 Loss, Tops Revenue Estimates
Assertio (ASRT) Reports Q1 Loss, Misses Revenue Estimates
4D Molecular Therapeutics, Inc. (FDMT) Reports Q1 Loss, Lags Revenue Estimates
Other News for VRCA
Verrica Pharmaceuticals (VRCA) Gains Approval for YCANTH in Japan
New 52 Week Closing Low appears for VRCA after 8.39% move
12 Health Care Stocks Moving In Friday's Pre-Market Session
Verrica Pharmaceuticals development partner receives approval for YCANTH
Verrica Pharmaceuticals development partner receives approval for YCANTH